2. NF-κB Metabolic Enzyme/Protease Immunology/Inflammation Apoptosis Anti-infection
  3. NF-κB Reactive Oxygen Species (ROS) Apoptosis Influenza Virus
  4. Picroside II

Picroside II is an antioxidant with oral activity that can reduce the production of ROS and protect the blood-brain barrier (BBB) after CI/R injury, offering neuroprotective effects. Picroside II has antioxidant, immune-regulating, antiviral properties, and inhibits apoptosis. Picroside II alleviates the inflammatory response in sepsis by suppressing the activation of the NLRP3 inflammasome and NF-κB pathways.

For research use only. We do not sell to patients.

CAS No. : 39012-20-9

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 4 publication(s) in Google Scholar

Other Forms of Picroside II:

Picroside II Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
Cell Migration/Invasion Assay
In Vivo Efficacy Study
WB

    Picroside II purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul:84:103665.  [Abstract]

    MTS proliferation assay to detect the proliferative ability of cells in Picroside II (300 μM)-treated and untreated groups.

    Picroside II purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul:84:103665.  [Abstract]

    Transwell migration assay treated with Picroside II (300 μM).

    Picroside II purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul:84:103665.  [Abstract]

    Images of subcutaneous xenografts from mice in Picroside II (0.4 mg/kg, i.p.)-treated and untreated groups.

    Picroside II purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Jul:84:103665.  [Abstract]

    Expression of MYOF, ILF3, OTUB1, LCN2 after Picroside II (300 μM) treatment.

    View All NF-κB Isoform Specific Products:

    View All Isoforms
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Picroside II is an antioxidant with oral activity that can reduce the production of ROS and protect the blood-brain barrier (BBB) after CI/R injury, offering neuroprotective effects. Picroside II has antioxidant, immune-regulating, antiviral properties, and inhibits apoptosis. Picroside II alleviates the inflammatory response in sepsis by suppressing the activation of the NLRP3 inflammasome and NF-κB pathways[1][2][3][4][5].

    In Vitro

    Picroside II (5-20 μM, 24 h) upregulates the expression of the bcl-2 gene in primary rat liver cells[1].
    Picroside II (0-300 μM, 24 h) inhibits the growth of HepG2 cells[2].
    Picroside II (10 μM, 20 h) reduces the transcription of genes involved in fatty acid uptake and synthesis in HepG2 cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Picroside II Related Antibodies

    RT-PCR[1]

    Cell Line: Primary rat hepatocytes
    Concentration: 5, 10, 20 μM
    Incubation Time: 24 h
    Result: Upregulated bcl-2.

    Cell Viability Assay[2]

    Cell Line: HepG2
    Concentration: 0, 3, 10, 30, 100, 300 μM
    Incubation Time: 24 h
    Result: Showed the inhibition rate of cell growth was 24%.

    Western Blot Analysis[2]

    Cell Line: HepG2
    Concentration: 10 μM
    Incubation Time: 20 h
    Result: Increased expression of SREBP-1 protein.

    RT-PCR[2]

    Cell Line: HepG2
    Concentration: 10 μM
    Incubation Time: 20 h
    Result: Down-regulated the expression of FATP5 and increased the expression of SCD mRNA.
    In Vivo

    Picroside II (0-20 mg/kg, i.g., given in two doses) protects liver cells from damage and prevents apoptosis[1].
    Picroside II (20 mg/kg, intravenous injection, given in four doses) inhibits the activation of NLRP3 inflammasome and NF-κB pathway in mice, reducing the inflammatory response in sepsis and enhancing immune function[3].
    Picroside II (20 mg/kg, intraperitoneal injection, a single dose) protects the blood-brain barrier by inhibiting oxidative signaling pathways in a rat model of ischemia-reperfusion injury[4].
    Picroside II (5-20 mg/kg, i.g., once a day for seven days) has anti-lipid peroxidation effects and protects against mitochondrial damage in mice with liver injury[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: DGalN and LPS(HY-D1056)-induced acute liver injury in mice[1]
    Dosage: 0, 5, 10, 20 mg/kg; administered 10 min before and 4 h after D-GalN and LPS administration
    Administration: i.g.
    Result: Reduced the levels of alanine aminotransferase and aspartate aminotransferase in the serum, decreased MDA content, had a dose-dependent effect on hepatocyte apoptosis, and upregulated the expression of the bcl-2 gene.
    Animal Model: Sepsis mouse model[3]
    Dosage: 20 mg/kg; four times injected (2 h, 14 h, 26 h and 38 h after CLP)
    Administration: Intravenous injection (i.v.)
    Result: Improved survival, reduced sepsis-related infiltration and attenuated lung injury, enhanced bacterial clearance, reduced IL-6, IL-1β, and TNF-α levels, inhibited splenic lymphocyte apoptosis, reduced p-NF-κB (p65) expression, and reduced IL-1β and caspase-1 levels.
    Animal Model: Rats with cerebral ischemia-reperfusion injury[4]
    Dosage: 20 mg/kg; single dose
    Administration: Intraperitoneal injection (i.p.)
    Result: Reduced the nervous system score, neuronal injury, BBB damage, ROS content and NADPH oxidase activity, down-regulated the protein levels of Rac-1, Nox2, ROCK, MLCK and MMP-2, and up-regulated the expression of claudin-5.
    Animal Model: Mouse model of liver injury induced by CCl4, D-GalN and AP[5]
    Dosage: 5, 10, 20mg/kg; daily; 7 days
    Administration: i.g.
    Result: Reduced the high levels of ALT and AST in serum caused by CCl4, D-GalN and AP, significantly alleviated liver cell damage, reduced MDA, and increased SOD and GSH-Px content in a dose-dependent manner, inhibited AP-induced liver toxicity in mice, enhanced ATPase activity, and improved mitochondrial swelling.
    Molecular Weight

    512.46

    Formula

    C23H28O13
    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1O[C@H]2[C@@]3([H])[C@@]([C@H](OC(C4=CC=C(O)C(OC)=C4)=O)[C@@]5([H])[C@]3(CO)O5)([H])C=CO2
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (195.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9514 mL 9.7569 mL 19.5137 mL
    5 mM 0.3903 mL 1.9514 mL 3.9027 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (4.88 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.91%

    SDS (392 KB)

    COA (252 KB) HNMR (292 KB) LCMS (94 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9514 mL 9.7569 mL 19.5137 mL 48.7843 mL
    5 mM 0.3903 mL 1.9514 mL 3.9027 mL 9.7569 mL
    10 mM 0.1951 mL 0.9757 mL 1.9514 mL 4.8784 mL
    15 mM 0.1301 mL 0.6505 mL 1.3009 mL 3.2523 mL
    20 mM 0.0976 mL 0.4878 mL 0.9757 mL 2.4392 mL
    25 mM 0.0781 mL 0.3903 mL 0.7805 mL 1.9514 mL
    30 mM 0.0650 mL 0.3252 mL 0.6505 mL 1.6261 mL
    40 mM 0.0488 mL 0.2439 mL 0.4878 mL 1.2196 mL
    50 mM 0.0390 mL 0.1951 mL 0.3903 mL 0.9757 mL
    60 mM 0.0325 mL 0.1626 mL 0.3252 mL 0.8131 mL
    80 mM 0.0244 mL 0.1220 mL 0.2439 mL 0.6098 mL
    100 mM 0.0195 mL 0.0976 mL 0.1951 mL 0.4878 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Picroside II Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Picroside II39012-20-9NF-κBReactive Oxygen Species (ROS)ApoptosisInfluenza VirusNuclear factor-κBNuclear factor-kappaBAnti-inflammatoryantioxidantheart ischemia-reperfusionapoptosisHepG2Inhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Picroside II
    Cat. No.:
    HY-N0408
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (392 KB) Français - FR (392 KB) Deutsch - DE (392 KB) Norwegian - NO (392 KB) Español - ES (392 KB) Swedish - SV (392 KB) Italian - IT (392 KB) Korean - KR (392 KB) Portuguese - PT (392 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.